Abstract
Background: Breast cancer (BC), the most frequent malignancy in women worldwide, is currently diagnosed in about 1.4 million female patients annually. Approximately 10-20% of BC is represented by triple negative breast cancer (TNBC) which is aggressive, the prognosis is poor and patients cannot benefit from targeted treatment based on hormonal or HER2 receptors. For this reason, search for markers that can predict the efficacy of chemotherapy in TNBC is a priority. Methods and Results: This review focuses on BCL2 protein as a prognostic marker in TNBC and its potential as a predictor of sensitivity to chemotherapy. Conclusion: BCL2 protein expression is a positive prognostic factor in BC. Better survival of patients with BCL2 positivity (BCL2+) has been explained by the correlation with estrogen receptor positive (ER+) status. BCL2+ is however not simply a surrogate marker for ER+. Moreover, BCL2 protein expression is also a positive prognostic marker in the TNBC subgroup. We and others show, that low BCL2 expression was associated with good outcome of TNBC patients treated with both adjuvant and neoadjuvant anthracycline-based chemotherapy. On the other hand, recent studies have shown that a subset of TNBC patients may benefit from the classical adjuvant CMF (cyclophosphamide, methotrexate, 5-fluorouracil) regimen. Given the heterogeneity of TNBC there is an urgent need to find and validate the sensitivity predictors to these regimens making them usable in clinical practice. BCL2 enrichment has been described in the mesenchymal stem-like (MSL) TNBC subgroup.
Keywords: Adjuvant chemotherapy, anthracycline, BCL2, neoadjuvant chemotherapy, predictive factor, prognostic factor, triple negative breast cancer.
Current Drug Targets
Title:Triple Negative Breast Cancer - BCL2 in Prognosis and Prediction. Review
Volume: 15 Issue: 12
Author(s): Katerina Bouchalova, Gvantsa Kharaishvili, Jan Bouchal, Jana Vrbkova, Magdalena Megova and Alice Hlobilkova
Affiliation:
Keywords: Adjuvant chemotherapy, anthracycline, BCL2, neoadjuvant chemotherapy, predictive factor, prognostic factor, triple negative breast cancer.
Abstract: Background: Breast cancer (BC), the most frequent malignancy in women worldwide, is currently diagnosed in about 1.4 million female patients annually. Approximately 10-20% of BC is represented by triple negative breast cancer (TNBC) which is aggressive, the prognosis is poor and patients cannot benefit from targeted treatment based on hormonal or HER2 receptors. For this reason, search for markers that can predict the efficacy of chemotherapy in TNBC is a priority. Methods and Results: This review focuses on BCL2 protein as a prognostic marker in TNBC and its potential as a predictor of sensitivity to chemotherapy. Conclusion: BCL2 protein expression is a positive prognostic factor in BC. Better survival of patients with BCL2 positivity (BCL2+) has been explained by the correlation with estrogen receptor positive (ER+) status. BCL2+ is however not simply a surrogate marker for ER+. Moreover, BCL2 protein expression is also a positive prognostic marker in the TNBC subgroup. We and others show, that low BCL2 expression was associated with good outcome of TNBC patients treated with both adjuvant and neoadjuvant anthracycline-based chemotherapy. On the other hand, recent studies have shown that a subset of TNBC patients may benefit from the classical adjuvant CMF (cyclophosphamide, methotrexate, 5-fluorouracil) regimen. Given the heterogeneity of TNBC there is an urgent need to find and validate the sensitivity predictors to these regimens making them usable in clinical practice. BCL2 enrichment has been described in the mesenchymal stem-like (MSL) TNBC subgroup.
Export Options
About this article
Cite this article as:
Bouchalova Katerina, Kharaishvili Gvantsa, Bouchal Jan, Vrbkova Jana, Megova Magdalena and Hlobilkova Alice, Triple Negative Breast Cancer - BCL2 in Prognosis and Prediction. Review, Current Drug Targets 2014; 15 (12) . https://dx.doi.org/10.2174/1389450115666141106151143
DOI https://dx.doi.org/10.2174/1389450115666141106151143 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
ZNF695, A Potential Prognostic Biomarker, Correlates with Im mune
Infiltrates in Cervical Squamous Cell Carcinoma and Endoce rvical
Adenocarcinoma: Bioinformatic Analysis and Experimental Verification
Current Gene Therapy Strategies for Stalling Malignancy: Targeting Cancers Addiction to Hsp90
Current Topics in Medicinal Chemistry Immunotherapy with Tumor Vaccines for the Treatment of Malignant Gliomas
Current Drug Discovery Technologies Natural Bioactive Compounds, Vegetal Extracts and Modern Pharmaceutical Formulations: New Insights into the Anti-Cancer Mechanism of Action
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Activity of N-Sulfonylamides of Tripeptides as Potential Urokinase Inhibitors
Protein & Peptide Letters Development of Novel Therapeutic Drugs in Humans from Plant Antimicrobial Peptides
Current Protein & Peptide Science Delineation of Current Development of Antimitotic Compounds Targeting Cytoskeletal Protein Tubulin and Microtubule in the Cancer Therapy
Current Chemical Biology Chronic Inflammatory Diseases: Progress and Prospect with Herbal Medicine
Current Pharmaceutical Design CDC25 Inhibitors as Anticancer Agents Are Moving Forward
Anti-Cancer Agents in Medicinal Chemistry Research and Development of Proteins and Peptides with Therapeutic Potential from Yam Tubers
Current Protein & Peptide Science A Case of Akathisia induced by Escitalopram: Case Report & Review of Literature
Current Drug Safety The Notch Signaling Pathway and Breast Cancer: The Importance of Balance and Cellular Self-Control
Current Signal Transduction Therapy Aberrant DNA Methylation and Prostate Cancer
Current Genomics Fragment-based Discovery of Potential Anticancer Lead: Computational and in vitro Studies
Current Computer-Aided Drug Design Biodegradable Polymeric Nanoparticles as the Delivery Carrier for Drug
Current Drug Delivery Unveiling the Transient Protein-Protein Interactions that Modulate the Activity of Estrogen Receptor(ER)-α by Human Lemur Tyrosine Kinase-3 (LMTK3) Domain: An In Silico Study
Current Proteomics The Development of Ataxia Telangiectasia Mutated Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Current Treatment of Relapsed Ovarian Carcinoma
Current Cancer Therapy Reviews Nonsteroidal Aromatase Inhibitors for the Treatment of Breast Cancer: An Update
Anti-Cancer Agents in Medicinal Chemistry Free Radicals in Diseases and Potential Role of Phytoconstituents-A Cause with Emerging Importance
Current Chemical Biology